Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p/RSF1 axis

References

• Siegel RL, Miller KD, Fuchs HE. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Dueñas-González A, Campbell S. Global strategies for the treatment of early-stage and advanced cervical cancer. Curr Opin Obstet Gynecol. 2016;28(1):11–17. doi: 10.1097/GCO.0000000000000234
   PubMed Web of Science ®Google Scholar
• Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019;123:316–323. doi: 10.1016/j.ypmed.2019.04.010
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Arbyn M. HPV-based cervical cancer screening- facts, fiction, and misperceptions. Prev Med. 2017;98:33–35. doi: 10.1016/j.ypmed.2016.12.040
   PubMed Web of Science ®Google Scholar
• Simms KT, Steinberg J, Caruana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20:394–407. doi: 10.1016/S1470-2045(18)30836-2
   PubMed Web of Science ®Google Scholar
• Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–e203. doi: 10.1016/S2214-109X(19)30482-6
   PubMed Web of Science ®Google Scholar
• Naga CP, Gurram L, Chopra S, et al. The management of locally advanced cervical cancer. Curr Opin Oncol. 2018;30:323–329. doi: 10.1097/CCO.0000000000000471
   PubMed Web of Science ®Google Scholar
• Olusola P, Banerjee HN, Philley JV, et al. Human papilloma virus-associated cervical cancer and health disparities. Cells. 2019;8(6):622. doi: 10.3390/cells8060622
   PubMed Web of Science ®Google Scholar
• Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925. doi: 10.1016/j.bioorg.2019.102925
   PubMed Web of Science ®Google Scholar
• Isohashi F, Takano T, Onuki M, et al. A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m(2) cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors. Int J Clin Oncol. 2019;24:575–582. doi: 10.1007/s10147-018-01380-z
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Zhang W, et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885–1895. doi: 10.2147/DDDT.S106412
   PubMed Web of Science ®Google Scholar
• Hombach S, Kretz M. Non-coding RNAs: classification, biology and functioning. Adv Exp Med Biol. 2016;937:3–17.
   PubMed Web of Science ®Google Scholar
• Beermann J, Piccoli MT, Viereck J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–1325. doi: 10.1152/physrev.00041.2015
   PubMed Web of Science ®Google Scholar
• Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816.
   PubMed Web of Science ®Google Scholar
• Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;56(1):55–66. doi: 10.1016/j.molcel.2014.08.019
   PubMed Web of Science ®Google Scholar
• Patop IL, Wüst S, Kadener S. Past, present, and future of circRnas. EMBO J. 2019;38(16):e100836. doi: 10.15252/embj.2018100836
   PubMed Web of Science ®Google Scholar
• Patop IL, Kadener S. circRNAs in Cancer. Curr Opin Genet Dev. 2018;48:121–127. doi: 10.1016/j.gde.2017.11.007
   PubMed Web of Science ®Google Scholar
• Chaichian S, Shafabakhsh R, Mirhashemi SM, et al. Circular RNAs: a novel biomarker for cervical cancer. J Cell Physiol. 2020;235(2):718–724. doi: 10.1002/jcp.29009
   PubMed Web of Science ®Google Scholar
• Cui C, Yang J, Li X, et al. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020;19(1):58. doi: 10.1186/s12943-020-01180-y
   PubMed Web of Science ®Google Scholar
• Chen M, Ai G, Zhou J, et al. circMTO1 promotes tumorigenesis and chemoresistance of cervical cancer via regulating miR-6893. Biomed Pharmacother. 2019;117:109064. doi: 10.1016/j.biopha.2019.109064
   PubMed Web of Science ®Google Scholar
• Guo J, Chen M, Ai G, et al. Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047. Biomed Pharmacother. 2019;115:108957. doi: 10.1016/j.biopha.2019.108957
   PubMed Web of Science ®Google Scholar
• Gao YL, Zhang MY, Xu B, et al. Circular RNA expression profiles reveal that hsa_circ_0018289 is up-regulated in cervical cancer and promotes the tumorigenesis. Oncotarget. 2017;8(49):86625–86633. doi: 10.18632/oncotarget.21257
   PubMedGoogle Scholar
• He J, Lv X, Zeng Z. A potential disease monitoring and prognostic biomarker in cervical cancer patients: The clinical application of circular RNA_0018289. J Clin Lab Analysis. 2020;34(8):e23340. doi: 10.1002/jcla.23340
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478). doi: 10.1126/science.aau6977
   PubMed Web of Science ®Google Scholar
• Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88(1):487–514. doi: 10.1146/annurev-biochem-013118-111902
   PubMed Web of Science ®Google Scholar
• Simpson RJ, Lim JW, Moritz RL, et al. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009;6(3):267–283. doi: 10.1586/epr.09.17
   PubMed Web of Science ®Google Scholar
• Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73(10):1907–1920. doi: 10.1016/j.jprot.2010.06.006
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019;1871(2):455–468. doi: 10.1016/j.bbcan.2019.04.004
   PubMed Web of Science ®Google Scholar
• Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75. doi: 10.1186/s12943-019-0991-5
   PubMed Web of Science ®Google Scholar
• Hon KW, Ab-Mutalib NS, Abdullah NMA. Extracellular Vesicle-derived circular RNAs confers chemoresistance in Colorectal cancer. Sci Rep. 2019;9(1):16497. doi: 10.1038/s41598-019-53063-y
   PubMed Web of Science ®Google Scholar
• Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–388. doi: 10.1038/nature11993
   PubMed Web of Science ®Google Scholar
• Panda AC. Circular RNAs act as miRNA sponges. Adv Exp Med Biol. 2018;1087:67–79.
   PubMed Web of Science ®Google Scholar
• Wang AH, Jin CH, Cui GY, et al. MIR210HG promotes cell proliferation and invasion by regulating miR-503-5p/TRAF4 axis in cervical cancer. Aging. 2020;12(4):3205–3217. doi: 10.18632/aging.102799
   PubMedGoogle Scholar
• Lin L, Xin B, Jiang T, et al. Long non-coding RNA LINC00460 promotes proliferation and inhibits apoptosis of cervical cancer cells by targeting microRNA-503-5p. Mol Cell Biochem. 2020;475(1–2):1–13. doi: 10.1007/s11010-020-03853-0
   PubMed Web of Science ®Google Scholar
• Xu K, Chen G, Qiu Y, et al. miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget. 2017;8(13):21719–21732. doi: 10.18632/oncotarget.15559
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National cancer Institute of the United States, National cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. doi: 10.1093/jnci/92.3.205
   PubMed Web of Science ®Google Scholar
• Li X, Li Y, Han Y, et al. Retracted: miR-205 promotes apoptosis of cervical cancer cells and enhances drug sensitivity of cisplatin by inhibiting YAP1. Cancer Biother Radiopharm. 2020;35(5):338–344. doi: 10.1089/cbr.2019.2983
   PubMed Web of Science ®Google Scholar
• Luo X, Wei J, Yang FL, et al. Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int. 2019;19(1):323. doi: 10.1186/s12935-019-1042-4
   PubMed Web of Science ®Google Scholar
• Raji GR, Sruthi TV, Edatt L, et al. Horizontal transfer of miR-106a/b from cisplatin resistant hepatocarcinoma cells can alter the sensitivity of cervical cancer cells to cisplatin. Cell Signal. 2017;38:146–158. doi: 10.1016/j.cellsig.2017.07.005
   PubMed Web of Science ®Google Scholar
• Su K, Wang CF, Zhang Y, et al. miR-940 upregulation contributes to human cervical cancer progression through p27 and PTEN inhibition. Int J Oncol. 2017;50(4):1211–1220. doi: 10.3892/ijo.2017.3897
   PubMed Web of Science ®Google Scholar
• Lin L, Li N, Hu X, et al. Identification of circ_0085616 as an upregulated and oncogenic circular RNA in cervical cancer via the miR-503-5p-mediated ATXN7L3 activation. Cancer Biother Radiopharm. 2020. doi:10.1089/cbr.2020.3865.
   Web of Science ®Google Scholar
• Fan S, Zhao S, Gao X, et al. Circular RNA circGSE1 promotes cervical cancer progression through miR-138-5p/Vimentin. Onco Targets Ther. 2020;13:13371–13386. doi: 10.2147/OTT.S282425
   PubMed Web of Science ®Google Scholar
• Gonzalez-Duarte RJ, Cazares-Ordonez V, Romero-Cordoba S, et al. Calcitriol increases Dicer expression and modifies the microRNAs signature in SiHa cervical cancer cells. Biochem Cell Biol. 2015;93(4):376–384. doi: 10.1139/bcb-2015-0010
   PubMedGoogle Scholar
• Kumar K, Bose S, Chakrabarti S. Identification of cross-pathway connections via protein-protein Interactions Linked to altered States of metabolic enzymes in cervical cancer. Front Med. 2021;8:736495. doi: 10.3389/fmed.2021.736495
   Web of Science ®Google Scholar
• Milane L, Singh A, Mattheolabakis G, et al. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–294. doi: 10.1016/j.jconrel.2015.06.029
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu J, Ma J, et al. Exosomal circRnas: biogenesis, effect and application in human diseases. Mol Cancer. 2019;18(1):116. doi: 10.1186/s12943-019-1041-z
   PubMed Web of Science ®Google Scholar
• Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25(8):981–984. doi: 10.1038/cr.2015.82
   PubMed Web of Science ®Google Scholar
• Qin X, Yu S, Zhou L, et al. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine. 2017;12:3721–3733. doi: 10.2147/IJN.S131516
   PubMed Web of Science ®Google Scholar
• Ran W, Zeng YH, Ma XJ, et al. The effect of miR-503-5p on the proliferation, invasion, migration and epithelial interstitium of cervical cancer HeLa cells via targeting E2 F3. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51:178–184. doi: 10.12182/20200360501
   PubMedGoogle Scholar
• Park GB, Kim D. MicroRNA-503-5p inhibits the CD97-mediated JAK2/STAT3 pathway in metastatic or paclitaxel-resistant ovarian cancer cells. Neoplasia. 2019;21(2):206–215. doi: 10.1016/j.neo.2018.12.005
   PubMed Web of Science ®Google Scholar
• Yoshino H, Seki N, Itesako T, et al. Aberrant expression of microRnas in bladder cancer. Nat Rev Urol. 2013;10(7):396–404. doi: 10.1038/nrurol.2013.113
   PubMed Web of Science ®Google Scholar
• Wang X, Sheu JJ, Lai MT, et al. RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer. Biomedicine. 2018;8:4. doi: 10.1051/bmdcn/2018080104
   PubMedGoogle Scholar
• Tian J, Kong E, Wang X, et al. RSF-1 siRNA enhances tumor radiosensitivity in cervical cancer via enhanced DNA damage, cell cycle redistribution, and promotion of apoptosis. onco Targets Ther. 2020;13:3061–3071. doi: 10.2147/OTT.S246632
   PubMed Web of Science ®Google Scholar
• He J, Fu L, Li Q. Rsf‑1 regulates malignant melanoma cell viability and chemoresistance via NF‑κB/Bcl‑2 signaling. Mol Med Rep. 2019;20:3487–3498. doi: 10.3892/mmr.2019.10610
   PubMed Web of Science ®Google Scholar
• Liu F, Tai Y, Ma J. LncRNA NEAT1/let-7a-5p axis regulates the cisplatin resistance in nasopharyngeal carcinoma by targeting rsf-1 and modulating the Ras-MAPK pathway. Cancer Biol Ther. 2018;19(6):534–542. doi: 10.1080/15384047.2018.1450119
   PubMed Web of Science ®Google Scholar